听力损失和临床不明显的先天性细胞巨乳病毒感染的婴儿中的瓦尔甘西克洛维尔:非随机对照试验
Pui Khi Chung1, Fleurtje A J Schornagel2, Wim Soede3
1Department of Medical Microbiology, Leiden University Medical Center, Leiden, The Netherlands.
The Journal of pediatrics
|February 9, 2024
概括
在患有 kongenital cytomegalovirus (cCMV) 和听力损失的婴儿中,瓦尔甘西克洛维尔治疗显示了听力改善的结果. 这项研究表明,瓦尔甘西克洛维尔可以预防临床不明显的cCMV的婴儿的听力恶化.
科学领域:
- 儿科 儿科 儿科
- 传染性疾病 传染性疾病
- 听力学 听力学是指听力学.
背景情况:
- 先天性细胞巨乳病毒 (cCMV) 是新生儿常见的病毒感染.
- 感觉神经听力损失是cCMV的常见并发症,即使在没有明显症状的情况下也是如此.
- 对于有听力损失和临床不明显的cCMV.婴儿,没有确立的治疗指南.
研究的目的:
- 评估瓦尔甘西克洛维尔在被诊断患有听力损失和亚临床先天性细胞巨乳病毒感染的婴儿中的有效性.
- 为了比较使用瓦尔甘西克洛维尔治疗的婴儿与没有接受治疗的婴儿的听力结果.
主要方法:
- 进行了一项全国性的非随机对照试验.
- 包括13周以下的感觉神经听力损失和被诊断为cCMV的婴儿.
- 这项研究比较了6周的口服瓦根西克洛维尔与不接受治疗,父母做出治疗决定.
主要成果:
- 这项研究包括37名婴儿 (25名接受治疗,12名对照),大多数患有轻微的神经成像异常.
- 听力恶化在接受瓦尔甘基克洛维尔治疗组 (OR 0.10,P=.003) 的可能性明显较小.
- 接受治疗的婴儿的平均听力改善为3.3dB,而对照组的听力恶化为13.7dB.
结论:
- 这是第一个前性,受控试验,研究甘环对有听力损失和不明显的cCMV的婴儿的治疗.
- 在这个人群中,瓦尔甘西克洛维尔治疗与未接受治疗相比,听力恶化较小.
- 这些发现表明,瓦尔甘西克洛维尔在保护cCMV和听力损失的婴儿的听力方面具有潜在的益处.
相关概念视频
01:31Hearing
48.1K
When we hear a sound, our nervous system is detecting sound waves—pressure waves of mechanical energy traveling through a medium. The frequency of the wave is perceived as pitch, while the amplitude is perceived as loudness.
48.1K
01:07Teratogenicity
4.2K
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
4.2K
01:29Drug Dosing: Infants and Children
1.0K
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
1.0K
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
414
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
414
01:18Viral Meningitis
219
Viral meningitis is the most common form of meningitis and is often referred to as aseptic meningitis to indicate the absence of bacterial involvement. It is generally milder than bacterial meningitis, with symptoms including fever, headache, stiff neck, drowsiness, nausea, photophobia, and vomiting. Rarely, more severe manifestations or death may occur. Common causative agents include enteroviruses, particularly coxsackie A and B viruses and echoviruses, all members of the Enterovirus genus...
219
01:27Cytomegalovirus Disease
108
Cytomegalovirus (CMV) disease is caused by human cytomegalovirus, a double-stranded DNA virus of the Herpesviridae family. While primary CMV infection is often asymptomatic in immunocompetent individuals, the virus can cause severe disease in neonates and immunocompromised patients. CMV is the most common cause of congenital viral infection in the United States, and a major pathogen in solid organ and hematopoietic stem cell transplant recipients.CMV is transmitted via bodily fluids, sexual...
108